

ASX Release

19th May 2015

Clinical Trial in Dogs for Treatment of Canine Cancers

SECOND DOG SHOWS SUPPRESSION OF CANCER MARKER AT DAYS 3 AND 7 FOLLOWING TREATMENT WITH PPL-1

PharmAust Limited (“PharmAust” or “the Company”) (ASX: PAA & PAAO) is pleased to announce that a further canine responded well to PPL-1 following the approval from the Department of Primary Industries (NSW) to amend the current canine trial protocol for the treatment of cancer in dogs (announced 13th April 2015). Like the first dog treated under the new protocol, the second dog demonstrated tumour marker suppression (p70S6K) of approximately 20% and 55% after three days and seven days of treatment respectively. This is further evidence that PPL-1 is active in canines by suppressing a tumour marker.

Principal investigator and dog cancer specialist, Dr Angela Frimberger, based at Veterinary Oncology Consultants Pty Ltd and the Animal Referral Hospital in Homebush, NSW said “This is further support for the use of PPL-1 in canine cancers. It is striking how rapidly PPL-1 imparts an effect on the tumour marker p70S6K, particularly since the drug appears to be of very low toxicity. The dogs being treated have late stage cancers with limited treatment options and the shorter treatment period recently approved by the authorities facilitate treatment of pets by their owners.”

The US companion pet market sales (est. 2011) are in the region of US\$14 billion whilst cancer therapies are estimated at \$550 million with a price point of around \$1,500 per treatment.

PharmAust’s Executive Chairman Dr Roger Aston said “As PPL-1 is already approved for veterinary use by PharmAust’s partner, a major global corporation in the Animal Health Industry, we believe that if successful in this trial, PPL-1 will be able to be approved quickly for the treatment of dog cancers following a further pivotal study”.

***References:**

2011-2012 National Pet Owners Survey Gabelli & Company, Inc. 2004. The US Veterinary health market.

<http://www.vet-dc.com/25.html>

American pet products manufacturers association, Inc. 2011-2012 National pet owner’s survey

For further details please contact:

Dr Roger Aston
Executive Chairman
Tel: 0402 762 204
rogeraston@pharmaust.com

Mr Robert Bishop
Executive Director
Tel: 0417 445 180
robertbishop@pharmaust.com